skip to Main Content

AIM-HI draws startups from the deep pipeline of National Foundation for Cancer Research (NFCR) funded scientists and the best-in-class global scientist-entrepreneur community.

Every year, hundreds of innovations and discoveries take place in research labs, academia, and leading cancer centers around the world. Surprisingly, only a small percentage ever make it into commercial ventures. The traditional commercialization approach facilitated by university technology transfer offices have met meager outcomes. 

Our Approach 

AIM-HI sources deals from a deep pipeline.  We leverage our relationships with NFCR and the Asian Foundation for Cancer Research to curate the best entrepreneurial projects, including those participating in and uncovered by their Salisbury Award for Entrepreneurial Translational Research and Bridging Research from Academia to Cancer Entrepreneurship (BRACE) Award programs. 

AIM-HI’s  venture accelerator approach  helps the scientist-entrepreneur focus on the technology while partnering with them to provide the necessary business, financial, legal and infrastructure support from the entrepreneurial ecosystem. 

AIM-HI has invested in the following outstanding startups, made up of scientist-entrepreneurs and their brilliant ideas with commercial potential. Please click on each company to read more of their story.

Akrotome Imaging, Inc

Akrotome Imaging, Inc

Innovation: Medical Imaging – molecular imaging to guide surgeons in performing a complete resection of tumor tissues during the first operation of Breast Conservation Surgery.
Targeted Cancer(s): 80% solid tumor cancers
Leadership: Brian Straight, President & CEO; Matthew Bogyo, PhD., Co-Founder; James Basilion, PhD., Co-Founder (Click here to view our team)
Stage of Business: Ready to Apply for Clinical Trial

Learn More…

Interleukin Combinatorial Therapies, Inc

Interleukin Combinatorial Therapies, Inc

Innovation: Therapeutics & drug discovery –  Cancer Terminator Viruses for the targeted therapy of a diverse array of aggressive tumor types
Targeted Cancer(s): GBM Melanoma
Leadership: Paul. B. Fisher, Ph.D., President and CEO; Webster Cavenee, Ph.D.
Stage of Business: Approved of Matching Funds from VCU for Phase I Clinical Trials

Learn More…

InVaMet Therapeutics

InVaMet Therapeutics

Innovation: Drug discovery –  small-molecule inhibitors of a specific cancer-promoting protein, MDA-9 PDZ
Targeted Cancer(s): Not Specified
Leadership: Paul. B. Fisher, Ph.D., President and CEO; Webster Cavenee, Ph.D.
Stage of Business: Matching Fund Application in Progress

Learn More…

Nonpareil Biotechnologies

Nonpareil Biotechnologies

Innovation: Therapeutics & drug discovery -converting oncology laboratory achievements into commercial products with market demands and regulatory approvals
Targeted Cancer(s): Multiple
Leadership: Joseph Swiader & Kenneth Sorensen, Co-Founders 
Stage of Business: Early stage. Prepare to apply for clinical trial

Learn More…

OncoHeros Biosciences

OncoHeros Biosciences

Innovation: Therapeutics & drug discovery –  novel biomarkers to repurpose and develop new drugs for pediatric cancer
Targeted Cancer(s): All types of pediatric cancer
Leadership: Ricardo Garcia, Founder & CEO; Cesare Spadoni PhD, MBA, Founder & COO; Marc Goldberg JD, MBA, Founder
Stage of Business: Received Matching Fund

Learn More…

Rasio Therapeutics

Rasio Therapeutics

Innovation: A drug Design software company, spinoff from SilcsBio
Targeted Cancer(s): Leukemia and other cancers
Leadership: Ken Malone, CEO; W. Alex Meltzer, Ph.D., VP of Drug Development (Click here to view our team)
Stage of Business:  Matching government funding in progress

Learn More…

SciTech Development, LLC

SciTech Development, LLC

Innovation: Therapeutics – unique nano-delivery systems (SciTech Delivery Vehicle-SDV) to enable intravenous (IV) delivery of water-insoluble drugs
Targeted Cancer(s): non-Hodgkin Lymphoma
Leadership: Earle T. Holsapple III; Michael Burns, PhD; Ralph E. Parchment, PhD (Click here to view our team)
Stage of Business: FDA approved IND in December 2019; ST-001 clinic ready; orphan drug designation granted in 2018

Learn More…

Stromatis Pharma

Stromatis Pharma

Innovation: Therapeutics – target stromal stellate cells for the treatment of cancer and fibrotic diseases
Targeted Cancer(s): Not Specified
Leadership: Guy Yachin, Partner & co-Founder; Cohava Gelber, Partner & co-Founder (Click here to view our team)
Stage of Business: Ready to Move into Phase I clinical trial in 2019

Learn More…

Tvardi Therapeutics

Tvardi Therapeutics

Innovation: Drug –  potential inhibitors of a protein, STAT-3, known to be associated with multiple cancers
Targeted Cancer(s): Hepatocellular Carcinoma, Triple-negative Breast Cancer, Lung Cancer, etc.
Leadership: Imran Alibhai, Ph.D, CEO; Jeno Gyuris, Ph.D; David Tweardy, M.D.; Ron DePinho, M.D. (Click here to view our team)
Stage of Business: Ready to Apply for Clinical Trial

Learn More…

YIVIVA

YIVIVA

Innovation: First-in-class botanical cancer platform drug
Targeted Cancer(s): Phase II Hepatitis B (+) Hepatocellular Carcinoma
Leadership: Peikwen Cheng, CEO; Yung-Chi Cheng, PhD Co-founder; Shwu-Huey Liu, PhD Co-founder and Chief Scientific Officer (Click here to view our team)
Stage of Business: Raised $7M Series A financing

Learn More…

Back To Top